Skip to main content
Top

Cellular Oncology

Issue 4/2018

Content (10 Articles)

Review

Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance

Pritish Nilendu, Sachin C. Sarode, Devashree Jahagirdar, Ishita Tandon, Shankargouda Patil, Gargi S. Sarode, Jayanta K. Pal, Nilesh Kumar Sharma

Original Paper

Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis

Noemi Eiro, Lucía González, Anxo Martínez-Ordoñez, Belen Fernandez-Garcia, Luis O. González, Sandra Cid, Francisco Dominguez, Román Perez-Fernandez, Francisco J. Vizoso

Original Paper

Genome-wide analysis of endogenously expressed ZEB2 binding sites reveals inverse correlations between ZEB2 and GalNAc-transferase GALNT3 in human tumors

Pelin Balcik-Ercin, Metin Cetin, Irem Yalim-Camci, Gorkem Odabas, Nurettin Tokay, A. Emre Sayan, Tamer Yagci

Original Paper

Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma

Zorica Milošević, Jasna Banković, Jelena Dinić, Chrisiida Tsimplouli, Evangelia Sereti, Miodrag Dragoj, Verica Paunović, Zorka Milovanović, Marija Stepanović, Nikola Tanić, Kostantinos Dimas, Milica Pešić

Open Access Original Paper

Patched-2 functions to limit Patched-1 deficient skin cancer growth

Veronique L. Veenstra, Ilse Dingjan, Cynthia Waasdorp, Helene Damhofer, Allard C. van der Wal, Hanneke W. van Laarhoven, Jan Paul Medema, Maarten F. Bijlsma

Report

AAA+ ATPases Reptin and Pontin as potential diagnostic and prognostic biomarkers in salivary gland cancer - a short report

Jan-Henrik Mikesch, Wolfgang Hartmann, Linus Angenendt, Otmar Huber, Christoph Schliemann, Maria Francisca Arteaga, Eva Wardelmann, Claudia Rudack, Wolfgang E. Berdel, Markus Stenner, Inga Grünewald

Correction

Correction to: The versatile role of exosomes in cancer progression: diagnostic and therapeutic implications

Vignesh Sundararajan, Fazlul H. Sarkar, Thamil Selvee Ramasamy

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine